

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : PILON, et al.

Serial No. : 08/864,357

Group Art Unit: 1812

Filed : May 28, 1997 .

Examiner: Romeo, David


For : USE OF RECOMBINANT HUMAN UTEROGLOBIN IN TREATMENT
OF INFLAMMATORY AND FIBROTIC CONDITIONS

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to Assistant Commissioner for Patents, Washington, D.C.
20231 on:

Date: 12/15/00

Signature: 
Robert E. Alderson, Jr., Reg. No. 44,500

Dear Sir:

AMENDMENT

This Amendment is submitted in response to the October 16, 2000 Official Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A response to the October 16, 2000 Official Action was originally due November 16, 2000. Applicants are filing concurrently a Petition for a One-Month Extension of Time. A response to the October 16, 2000 Official Action with a one-month extension of time is due December 16, 2000. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

IN THE SPECIFICATION

Page 12, line 10, after “proteins,” please delete “(SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; and SEQ ID NO: 21)”.

Page 19, line 3, after “have previously shown the addition of,” please delete “Met-Ala-Ala-Met” and insert --Met-Ala-Ala--.

Page 20, line 1, please delete “SEQ ID NO: 1”;

line 3, please delete “SEQ ID NO: 2”;

line 5, please delete “SEQ ID NO: 3”;

line 7, please delete “SEQ ID NO: 4”;

line 8, please delete “SEQ ID NO: 5”;

line 10, please delete “SEQ ID NO: 6”

line 12, please delete “SEQ ID NO: 7”;

line 14, please delete “SEQ ID NO: 8”.

Page 32, line 15, after “(from Intron 1):” please delete “SEQ ID NO: 9”.

Page 34, line 2, after “mPr” please delete “SEQ ID NO: 10”;

line 4, after “mPl” please delete “SEQ ID NO: 11”;

line 5, after “mPp” please delete “SEQ ID NO. 12”;

line 7, after “mGAPDH-r” please delete “SEQ ID NO: 13”;

line 8, after mGAPDH-1” please delete “SEQ ID NO: 14”; same line, after “mGAPDH-p” please delete “SEQ ID NO: 15”.

Page 35, penultimate line, before “KPFNPGSDLQNAGTQLKRLVDT)” please delete “SEQ ID NO: 17”.

Please insert the attached paper copy of the Sequence Listing at the end of the subject specification.

Remarks

Applicants would like to thank Examiner Romeo for the courtesies extended to applicants' attorney during several recent informal telephone conferences in connection with the above-identified application.

The amendment to the specification on page 19, line 4, was made to correct a typographical error. (Please see Mantile et al. (1993) page 20346, Col. 1, which confirms that SEQ. ID. NO. 5 should be Met-Ala-Ala.)

Objection to the Specification

The specification was objected to for having sequences identified by more than one SEQ ID NO. Applicants have hereinabove amended the specification to delete multiple sequence identification numbers. Applicants believe that this Amendment corrects all such duplications and that each sequence in the specification is now identified by a single sequence identification number.

The specification also was objected to for failure to comply with sequence rules. In response, applicants attach as **Exhibit A** a corrected paper copy of the sequence listing. Applicants also submit herewith a computer readable form (CRF) of the sequence listing. Applicants maintain that the content of the paper and the CRF copies are the same and do not include new matter. Applicants attach as **Exhibit B** a copy of the Notice to Comply.


In view of the foregoing, applicants respectfully request that the Examiner reconsider and withdraw the objections set forth in the October 16, 2000 Official Action.

PILON et al
Serial No. 08/864,357

No fee, other than the fee for a one-month extension of time, is believed to be necessary in connection with the filing of this Amendment. However, if any additional fee is necessary, applicants hereby authorize such fee to be charged to Deposit Account No. 50-0540.

Respectfully submitted,

Dated: 12/15/00

By: 

Robert E. Alderson, Jr.
Registration No. 44,500
Attorney for Applicants
KRAMER LEVIN NAFTALIS & FRANKEL LLP
919 Third Avenue
New York, New York 10022
(212) 715-7697